Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Shares Outstanding (Weighted Average) (2016 - 2025)

Avalo Therapeutics filings provide 12 years of Shares Outstanding (Weighted Average) readings, the most recent being $13.4 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 202.86% to $13.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $13.4 million, a 202.86% increase, with the full-year FY2025 number at $13.4 million, up 202.86% from a year prior.
  • Shares Outstanding (Weighted Average) hit $13.4 million in Q4 2025 for Avalo Therapeutics, down from $14.0 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $88.6 million in Q1 2021 to a low of $39202.0 in Q4 2022.
  • Median Shares Outstanding (Weighted Average) over the past 5 years was $8.0 million (2021), compared with a mean of $10.0 million.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): crashed 99.53% in 2022 and later skyrocketed 1676.34% in 2024.
  • Avalo Therapeutics' Shares Outstanding (Weighted Average) stood at $8.3 million in 2021, then crashed by 99.53% to $39202.0 in 2022, then surged by 608.45% to $277727.0 in 2023, then soared by 1493.7% to $4.4 million in 2024, then skyrocketed by 202.86% to $13.4 million in 2025.
  • The last three reported values for Shares Outstanding (Weighted Average) were $13.4 million (Q4 2025), $14.0 million (Q3 2025), and $10.8 million (Q2 2025) per Business Quant data.